Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer-Reference-Cited by-同舟云学术

Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer

Published:2019-04-25 Issue:1 Volume:12 Page:
ISSN:1757-2215
Container-title:Journal of Ovarian Research
language:en
Short-container-title:J Ovarian Res

Author:

Cohen Samantha,Schwartz Melissa^ORCID,Dottino Peter,Beddoe Ann Marie

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynaecology,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s13048-019-0506-4.pdf

Reference28 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.

2. Slaughter K, Holman LL, Thomas EL, Gunderson CC, Lauer JK, Ding K, et al. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016;142(2):225–30.

3. Herzog TJ, Armstrong DK, et al. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper. Gynecol Oncol. 2014;132:8–17.

4. Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014;5(3):186–92.

5. Kerbel R, Karmen B. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–6.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced anti-tumor efficacy with multi-transgene armed mesenchymal stem cells for treating peritoneal carcinomatosis;Journal of Translational Medicine;2024-05-15

2. A Comprehensive Study on Folate-Targeted Mesoporous Silica Nanoparticles Loaded with 5-Fluorouracil for the Enhanced Treatment of Gynecological Cancers;Journal of Functional Biomaterials;2024-03-20

3. Clinical efficacy and safety of docetaxel in combination with cisplatin on the platin-sensitive recurrent ovarian cancer in comparison of whole abdominal radiotherapy;International Journal of Radiation Research;2022-01-01

4. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells;HISTOL HISTOPATHOL;2021

5. Antineoplastics;Reactions Weekly;2019-06